University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial GOG-0241


A GCIG Intergroup Multi-Center Phase III Trial of Open-Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent Bevacizumab (NSC #704865, IND #113912) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First-Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC).

Type: Cancer Therapy
Phase: Phase III
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Anti-Angiogenesis, Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Huyen Q. Pham, M.D.
Other Trial Staff:  Kristy Watkins, R.N., Grace Facio, R.N., Marissa Aldana, D.M., Yvonne Flores, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.